| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jun Soo Kwon, Euitae Kim, Do-Hyung Kang, Jung Seok Choi, Kyung-Sang Yu, In-Jin Jang, Sang-Goo Shi. Taq1A polymorphism in the dopamine D2 receptor gene as a predictor of clinical response to aripiprazole. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 18. issue 12. 2009-04-20. PMID:18786813. |
we investigated whether the clinical response to aripiprazole differed according to the taq1a polymorphism in the dopamine d2 receptor (drd2) gene. |
2009-04-20 |
2023-08-12 |
Not clear |
| Asa Wallén-Mackenzie, Karin Nordenankar, Kim Fejgin, Malin C Lagerström, Lina Emilsson, Robert Fredriksson, Caroline Wass, Daniel Andersson, Emil Egecioglu, My Andersson, Joakim Strandberg, Orjan Lindhe, Helgi B Schiöth, Karima Chergui, Eric Hanse, Bengt Långström, Anders Fredriksson, Lennart Svensson, Erika Roman, Klas Kullande. Restricted cortical and amygdaloid removal of vesicular glutamate transporter 2 in preadolescent mice impacts dopaminergic activity and neuronal circuitry of higher brain function. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 29. issue 7. 2009-04-16. PMID:19228977. |
a connection between the induced late-onset, chronic reduction of glutamatergic neurotransmission and dopamine signaling within the circuitry was further substantiated by a partial attenuation of the deficits in sensorimotor gating by the dopamine-stabilizing antipsychotic drug aripiprazole and an increased sensitivity to amphetamine. |
2009-04-16 |
2023-08-12 |
mouse |
| Mong-Liang Lu, Winston W Shen, Chun-Hsin Che. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Progress in neuro-psychopharmacology & biological psychiatry. vol 32. issue 8. 2009-04-15. PMID:18848860. |
the prolactin-normalizing effects of aripiprazole are likely caused by the unique characteristics of the dopamine partial agonist with its high affinity for dopamine d2 receptors. |
2009-04-15 |
2023-08-12 |
human |
| Irismar Reis de Oliveira, Hélio Elkis, Wagner Farid Gattaz, Ana Cristina Chaves, Eduardo Pondé de Sena, Fabio Gomes de Matos E Souza, João Alberto Campos, João Romildo Bueno, Jorge Alberto Costa E Silva, Mário Rodrigues Louzã, Paulo Belmonte de Abre. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS spectrums. vol 14. issue 2. 2009-04-01. PMID:19238124. |
aripiprazole, a dopamine d2 receptor partial agonist, has also partial agonist activity at serotonin (5-ht)1a receptors and antagonist activity at 5-ht2a receptors. |
2009-04-01 |
2023-08-12 |
Not clear |
| Minoru Narita, Daisuke Takei, Mitsuru Shiokawa, Yuri Tsurukawa, Yuki Matsushima, Atsushi Nakamura, Shigemi Takagi, Megumi Asato, Daigo Ikegami, Michiko Narita, Taku Amano, Keiichi Niikura, Keisuke Hashimoto, Naoko Kuzumaki, Tsutomu Suzuk. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. European journal of pharmacology. vol 600. issue 1-3. 2009-03-27. PMID:18955042. |
the increased level of dialysate dopamine in the nucleus accumbens stimulated by morphine was significantly decreased by pretreatment with aripiprazole. |
2009-03-27 |
2023-08-12 |
mouse |
| Lawrence S Kegeles, Mark Slifstein, W Gordon Frankle, Xiaoyan Xu, Elizabeth Hackett, Sung-A Bae, Robyn Gonzales, Jong-Hoon Kim, Beatriz Alvarez, Roberto Gil, Marc Laruelle, Anissa Abi-Dargha. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18418366. |
dose-occupancy study of striatal and extrastriatal dopamine d2 receptors by aripiprazole in schizophrenia with pet and [18f]fallypride. |
2009-02-19 |
2023-08-12 |
Not clear |
| Lawrence S Kegeles, Mark Slifstein, W Gordon Frankle, Xiaoyan Xu, Elizabeth Hackett, Sung-A Bae, Robyn Gonzales, Jong-Hoon Kim, Beatriz Alvarez, Roberto Gil, Marc Laruelle, Anissa Abi-Dargha. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18418366. |
correlations of ratings of clinical improvement with regional occupancy suggest that aripiprazole, as do other antipsychotics, benefits positive symptoms of schizophrenia most directly through its modulation of striatal rather than cortical or other extrastriatal dopamine activity. |
2009-02-19 |
2023-08-12 |
Not clear |
| Konstantin Voronin, Patrick Randall, Hugh Myrick, Raymond Anto. Aripiprazole effects on alcohol consumption and subjective reports in a clinical laboratory paradigm--possible influence of self-control. Alcoholism, clinical and experimental research. vol 32. issue 11. 2009-02-09. PMID:18782344. |
aripiprazole has the unique pharmacology of being a partial dopamine agonist serving to stabilize brain dopamine systems in both frontal cortical and subcortical areas. |
2009-02-09 |
2023-08-12 |
Not clear |
| Thomas F Newton, Malcolm S Reid, Richard De La Garza, James J Mahoney, Antonio Abad, Rany Condos, Joseph Palamar, Perry N Halkitis, Jurji Mojisak, Ann Anderson, Shou-Hua Li, Ahmed Elkashe. Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. The international journal of neuropsychopharmacology. vol 11. issue 8. 2009-01-26. PMID:18664303. |
in this study, we investigated the safety and potential efficacy of aripiprazole, an antipsychotic agent acting on both dopamine and serotonin systems. |
2009-01-26 |
2023-08-12 |
human |
| Andrea Gogos, Mirjana Bogeski, Maarten van den Buus. Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology. Behavioural pharmacology. vol 19. issue 5-6. 2008-12-31. PMID:18690109. |
in balb/c mice, the effect of 8-oh-dpat was blocked by the typical antipsychotic and dopamine d2 receptor antagonist, haloperidol and the third generation antipsychotic, aripiprazole, which has activity at both 5-ht1a and dopamine d2 receptors. |
2008-12-31 |
2023-08-12 |
mouse |
| Arif Kha. Current evidence for aripiprazole as augmentation therapy in major depressive disorder. Expert review of neurotherapeutics. vol 8. issue 10. 2008-12-29. PMID:18928339. |
the pharmacological basis of the action of aripiprazole in major depressive disorder remains unclear, but it may be related to its potent partial agonism of the dopamine d(2)/d(3) receptors, partial agonism of the 5-hydroxytryptamine (5-ht)(1a) receptor and antagonism of the 5-ht(2a) receptor. |
2008-12-29 |
2023-08-12 |
Not clear |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. European journal of pharmacology. vol 597. issue 1-3. 2008-12-16. PMID:18831971. |
characterization of aripiprazole partial agonist activity at human dopamine d3 receptors. |
2008-12-16 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. European journal of pharmacology. vol 597. issue 1-3. 2008-12-16. PMID:18831971. |
aripiprazole is the first dopamine d2/d3 receptor partial agonist approved for use in the treatment of psychiatric disorders, including schizophrenia, bipolar disorder, and unipolar depression in the us. |
2008-12-16 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. European journal of pharmacology. vol 597. issue 1-3. 2008-12-16. PMID:18831971. |
to explore the functional activity of aripiprazole at dopamine d3 receptors, we established chinese hamster ovary (cho) cell lines stably expressing high and low densities of ser-9 and gly-9 variants of human dopamine d3 receptors and compared aripiprazole's dopamine d3 pharmacological properties with other marketed and non-approved dopamine d3 receptor modulating agents on inhibition of forskolin-stimulated camp accumulation. |
2008-12-16 |
2023-08-12 |
human |
| Yoshihiro Tadori, Robert A Forbes, Robert D McQuade, Tetsuro Kikuch. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. European journal of pharmacology. vol 597. issue 1-3. 2008-12-16. PMID:18831971. |
aripiprazole's unique activity at dopamine d3 receptors may translate into clinically relevant outcomes in patients with a variety of neuropsychiatric disorders. |
2008-12-16 |
2023-08-12 |
human |
| Gunnar Sørensen, Thomas N Sager, Jørgen H Petersen, Lise T Brennum, Peter Thøgersen, Cecilie Hee Bengtsen, Morgane Thomsen, Gitta Wörtwein, Anders Fink-Jensen, David P D Woldby. Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice. Psychopharmacology. vol 199. issue 1. 2008-12-03. PMID:18481046. |
the novel antipsychotic aripiprazole in use for treatment of schizophrenia is a partial agonist at dopamine d2 receptors with actions at a variety of other receptors as well. |
2008-12-03 |
2023-08-12 |
mouse |
| Robert L Findling, Adelaide Robb, Margaretta Nyilas, Robert A Forbes, Na Jin, Svetlana Ivanova, Ronald Marcus, Robert D McQuade, Taro Iwamoto, William H Carso. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American journal of psychiatry. vol 165. issue 11. 2008-11-18. PMID:18765484. |
aripiprazole is a dopamine partial agonist approved for use in adults for short- and long-term treatment of schizophrenia and bipolar disorder. |
2008-11-18 |
2023-08-12 |
Not clear |
| E Vieta, C Franc. [Advances in the treatment of mania: aripiprazole]. Actas espanolas de psiquiatria. vol 36. issue 3. 2008-09-26. PMID:18478456. |
aripiprazole is a dopamine partial agonist antipsychotic drug that has just been approved in europe for its use in the treatment of acute mania and for the prevention of manic episodes in bipolar disorder. |
2008-09-26 |
2023-08-12 |
Not clear |
| Takahiro Kato, Yoshito Mizoguchi, Akira Monji, Hideki Horikawa, Satoshi O Suzuki, Yoshihiro Seki, Toru Iwaki, Sadayuki Hashioka, Shigenobu Kanb. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. Journal of neurochemistry. vol 106. issue 2. 2008-09-16. PMID:18429930. |
aripiprazole is a novel atypical antipsychotic, which is a high-affinity dopamine d(2) receptor partial agonist. |
2008-09-16 |
2023-08-12 |
Not clear |
| Takahiro Kato, Yoshito Mizoguchi, Akira Monji, Hideki Horikawa, Satoshi O Suzuki, Yoshihiro Seki, Toru Iwaki, Sadayuki Hashioka, Shigenobu Kanb. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. Journal of neurochemistry. vol 106. issue 2. 2008-09-16. PMID:18429930. |
not quinpirole, dopamine d(2) full agonist, but aripiprazole significantly inhibited the generation of nitric oxide (no) and tumor necrosis factor (tnf)-alpha from ifn-gamma-activated microglia and suppressed the ifn-gamma-induced elevation of intracellular ca(2+) concentrations ([ca(2+)](i)) in murine microglial cells. |
2008-09-16 |
2023-08-12 |
Not clear |